High Risk Smoldering Multiple Myeloma (HR-SMM) Clinical Trials in Boston, Massachusetts

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)